Search research articles
Contact Us
Filters
Showing results (61-70 of 66) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 66 results.
Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society
|
March 17, 2026
Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease
Hadeel Drweesh, Amal Alotaibi, Hussain Abdalghani Alqassim, et al.
Antimicrobial Agents and Chemotherapy
|
May 8, 2019
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
Mohammad H Al-Shaer, Wael A Alghamdi, Abdullah Alsultan, et al.
Antimicrobial Agents and Chemotherapy
|
July 8, 2020
Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis
Mohammad H Al-Shaer, Anne-Grete Märtson, Wael A Alghamdi, et al.
Antimicrobial Agents and Chemotherapy
|
March 13, 2019
Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis
Wael A Alghamdi, Abdullah Alsultan, Mohammad H Al-Shaer, et al.
Plos One
|
October 12, 2013
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study
Caitrin W McDonough, Nancy K Gillis, Abdullah Alsultan, et al.
Antimicrobial Agents and Chemotherapy
|
December 6, 2021
Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis
Ju Sang Kim, Yong-Hyun Kim, Sang Haak Lee, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 66) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 66 results.
Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society
|
March 17, 2026
Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease
Hadeel Drweesh, Amal Alotaibi, Hussain Abdalghani Alqassim, et al.
Antimicrobial Agents and Chemotherapy
|
May 8, 2019
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
Mohammad H Al-Shaer, Wael A Alghamdi, Abdullah Alsultan, et al.
Antimicrobial Agents and Chemotherapy
|
July 8, 2020
Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis
Mohammad H Al-Shaer, Anne-Grete Märtson, Wael A Alghamdi, et al.
Antimicrobial Agents and Chemotherapy
|
March 13, 2019
Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis
Wael A Alghamdi, Abdullah Alsultan, Mohammad H Al-Shaer, et al.
Plos One
|
October 12, 2013
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study
Caitrin W McDonough, Nancy K Gillis, Abdullah Alsultan, et al.
Antimicrobial Agents and Chemotherapy
|
December 6, 2021
Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis
Ju Sang Kim, Yong-Hyun Kim, Sang Haak Lee, et al.
Page
of 7